← All trials
NCT04741204
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Jul 31, 2025
- First posted
- Feb 5, 2021
- Last posted
- Nov 24, 2021
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Pennington Biomedical Research CenterLead sponsor
- PfizerCollaborator
- American Cancer Society, Inc.Collaborator
- Our Lady of the Lake Regional Medical CenterCollaborator
- Woman's Hospital, LouisianaStudy chair
- Mary Bird Perkins Cancer centerStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.